Article
Rheumatology
Kevin L. Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi, Alan Kivitz, Franziska Matzkies, Mark C. Genovese, Deyuan Jiang, Kun Chen, Beatrix Bartok, Angelika Jahreis, Robin Besuyen, Gerd R. Burmester, Jacques-Eric Gottenberg
Summary: In patients with moderately to severely active rheumatoid arthritis, the safety and tolerability of Filgotinib were good, with a lower incidence of infections in the Filgotinib 200 mg dose group compared to placebo during long-term treatment.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Farzin Khosrow-Khavar, Seoyoung C. Kim, Hemin Lee, Su Been Lee, Rishi J. Desai
Summary: The study did not find evidence of increased cardiovascular risk with tofacitinib in patients with RA in a real-world setting. However, tofacitinib was associated with an increased risk of cardiovascular outcomes, although statistically non-significant, in patients with RA with cardiovascular risk factors.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Rene Westhovens, William F. C. Rigby, Desiree van der Heijde, Daniel W. T. Ching, William Stohl, Jonathan Kay, Arvind Chopra, Beatrix Bartok, Franziska Matzkies, Zhaoyu Yin, Ying Guo, Chantal Tasset, John S. Sundy, Angelika Jahreis, Neelufar Mozaffarian, Osvaldo Daniel Messina, Robert B. M. Landewe, Tatsuya Atsumi, Gerd R. Burmester
Summary: The study showed that Filgotinib significantly improved symptoms and physical function in active RA patients treated in combination with MTX, while FIL200 monotherapy did not show a significant advantage in ACR20 response rate compared to MTX.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Lotte van Ouwerkerk, Patrick Verschueren, Maarten Boers, Paul Emery, Pascal Hendrik Pieter de Jong, Robert B. M. Landewe, Willem Lems, Josef S. Smolen, Tom W. J. Huizinga, Cornelia F. Allaart, Sytske Anne Bergstra
Summary: In patients with rheumatoid arthritis (RA), the use of glucocorticoids (GC) as bridging therapy resulted in a more rapid clinical improvement and fewer changes in medication, but similar long-term GC use compared with patients who did not receive bridging therapy.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Claire Daien, Marek Krogulec, Paul Gineste, Jean-Marc Steens, Laurence Desroys du Roure, Sophie Biguenet, Didier Scherrer, Julien Santo, Hartmut Ehrlich, Patrick Durez
Summary: This study evaluated the safety and efficacy of ABX464 in patients with moderate-to-severe active rheumatoid arthritis. The results showed that ABX464 at a 50 mg dose was safe, well tolerated, and showed promising efficacy. The 100 mg dose had a high dropout rate due to gastrointestinal adverse events.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Dafne Capelusnik, Daniel Aletaha
Summary: In rheumatoid arthritis treatment, lower baseline disease activity levels are associated with achieving disease state targets, while male gender, shorter disease duration, and lower disease activity levels can improve predictability of state targets.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Sakir Ahmed, Pankti Mehta, Aby Paul, S. Anu, Somy Cherian, Veena Shenoy, Kaveri K. Nalianda, Sanjana Joseph, Anagha Poulose, Padmanabha Shenoy
Summary: This study assessed the incidence and risk factors for breakthrough COVID-19 infections in vaccinated patients with autoimmune rheumatic diseases (AIRDs) and found that the levels of antibodies against the receptor binding domain of spike protein were associated with susceptibility to such infections. Breakthrough infections occurred in 7.4% of patients and were associated with seronegativity following vaccination.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
David Moulin, Marie Millard, Mahdia Taieb, Chloe Michaudel, Anne Aucouturier, Antoine Lefevre, Luis G. Bermudez-Humaran, Philippe Langella, Youssouf Sereme, Kristell Wanherdrick, Preeti Gautam, Xavier Mariette, Philippe Dieude, Jacques-Eric Gottenberg, Jean-Yves Jouzeau, David Skurnik, Patrick Emond, Denis Mulleman, Jeremie Sellam, Harry Sokol
Summary: This study investigates the alterations in tryptophan metabolism in rheumatoid arthritis (RA) and their potential as therapeutic targets. The results show significant changes in Trp metabolite levels in RA patients compared to healthy controls, and these alterations are associated with disease severity and quality of life. The study also demonstrates the therapeutic potential of targeting the kynurenine pathway in RA.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Walter Reinisch, Wayne Hellstrom, Radboud J. E. M. Dolhain, Suresh Sikka, Rene Westhovens, Rajiv Mehta, Timothy Ritter, Ursula Seidler, Oleksandr Golovchenko, Vladimir Simanenkov, Olena Garmish, Slawomir Jeka, Radka Moravcova, Vijay Rajendran, Franck-Olivier Le Brun, Sarah Arterburn, Timothy R. Watkins, Robin Besuyen, Dirk Vanderschueren
Summary: The phase 2 MANTA and MANTA-RAy studies aimed to determine the impact of the oral Janus kinase 1 inhibitor filgotinib on semen parameters and sex hormones in men with inflammatory diseases. Results showed that once daily filgotinib 200 mg for 13 weeks had no measurable impact on semen parameters or sex hormones.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Joanna Kedra, Alexandre Lafourcade, Bernard Combe, Maxime Dougados, David Hajage, Bruno Fautrel
Summary: This study assessed the impact of disease-modifying antirheumatic drugs (DMARDs) on 10-year outcomes in patients with rheumatoid arthritis (RA) and found that early initiation of conventional synthetic DMARDs can reduce the risk of functional and structural outcomes.
Article
Rheumatology
Ara H. Dikranian, Miguel A. Gonzalez-Gay, Frank Wellborne, Jose Maria Alvaro-Gracia, Liza Takiya, Lori Stockert, Jerome Paulissen, Harry Shi, Svitlana Tatulych, Jeffrey R. Curtis
Summary: This post hoc analysis assessed the impact of baseline body mass index (BMI) on the efficacy of tofacitinib in treating rheumatoid arthritis. The results showed that tofacitinib demonstrated greater efficacy improvements compared to placebo in different BMI categories, and there was no consistent association between BMI and treatment outcomes.
Article
Rheumatology
Daniel Aletaha, Clifton O. Bingham, George Athanasios Karpouzas, Tsutomu Takeuchi, Carter Thorne, Androniki Bili, Prasheen Agarwal, Benjamin Hsu, Ravi Rao, Kurt Brown, Yoshiya Tanaka
Summary: Sirukumab, a human monoclonal antibody targeting IL-6, demonstrated consistent safety and efficacy in the long-term extension study, with reductions in RA symptoms and improvements in physical function sustained over time.
Article
Rheumatology
Daniel Aletaha, Rene Westhovens, Cecile Gaujoux-Viala, Giovanni Adami, Alan Matsumoto, Paul Bird, Osvaldo Daniel Messina, Maya H. Buch, Beatrix Bartok, Zhaoyu Yin, Ying Guo, Thijs Hendrikx, Gerd R. Burmester
Summary: The analysis evaluated the efficacy and safety of filgotinib in MTX-naive patients with RA and multiple poor prognostic factors. The combination of FIL200 + MTX showed comparable efficacy and safety to the overall population, while FIL100 + MTX and FIL200 were not consistently more efficacious than MTX monotherapy.
Article
Rheumatology
Saeko Yamada, Yasuo Nagafuchi, Min Wang, Mineto Ota, Hiroaki Hatano, Yusuke Takeshima, Mai Okubo, Satomi Kobayashi, Yusuke Sugimori, Nakano Masahiro, Ryochi Yoshida, Norio Hanata, Yuichi Suwa, Yumi Tsuchida, Yukiko Iwasaki, Shuji Sumitomo, Kanae Kubo, Kenichi Shimane, Keigo Setoguchi, Takanori Azuma, Hiroko Kanda, Hirofumi Shoda, Xuan Zhang, Kazuhiko Yamamoto, Kazuyoshi Ishigaki, Tomohisa Okamura, Keishi Fujio
Summary: By analyzing the transcriptome of peripheral blood immune cell subsets in patients with rheumatoid arthritis (RA), immune cells that predict treatment resistance were identified. Changes in the transcriptome and treatment effects in RA were characterized. Plasmacytoid dendritic cells (pDC) showed the strongest association with treatment resistance. The predictive value of pDC-related gene expression and pDC proportion in treatment-resistant patients was validated in independent cohorts.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Shunsuke Mori, Yukitomo Urata, Tamami Yoshitama, Yukitaka Ueki
Summary: The study found that tofacitinib was more effective in inducing greater improvements in bDMARD-naive patients with active RA during the first 12 months of treatment compared to tocilizumab, but this difference was not observed in bDMARD-failure patients.
Article
Immunology
Kristina Lejon, Urban Hellman, Anjani Kumar, Helena Forsblad-d'Elia
Summary: The purpose of this study was to investigate the changes in different cell types and disease-related factors in patients with ankylosing spondylitis (AS) from northern Sweden. The study found a significant reduction in the number of TFH cells, plasmablasts, and B memory cells in AS patients, which may be related to an aberrant humoral immune response associated with inflammation. Some cell types in female patients were negatively correlated with inflammation markers.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
(2023)
Article
Rheumatology
Matilda Morin, Thomas Frisell, Olof Stephansson, Karin Hellgren
Summary: This study aimed to assess the risks of adverse pregnancy outcomes in women with axial spondyloarthritis and investigate how the outcomes varied over time and with anti-rheumatic treatment. The results showed increased risks of preterm birth, pre-eclampsia, elective caesarean delivery, and serious infant infection in women with axial spondyloarthritis compared to the general population. However, there was a trend of improvement in pregnancy outcomes over time, coinciding with increased use of biological DMARDs.
LANCET RHEUMATOLOGY
(2023)
Article
Rheumatology
Thomas Frisell, Hannah Bower, Matilda Morin, Eva Baecklund, Daniela Di Giuseppe, Benedicte Delcoigne, Nils Feltelius, Helena Forsblad-d'Elia, Elisabet Lindqvist, Ulf Lindstroem, Johan Askling
Summary: The objective of this study was to assess and compare the incidence rates of key safety outcomes for individual targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) in rheumatoid arthritis (RA). The study found that the b/tsDMARDs currently used to treat RA have acceptable and largely similar safety profiles, but differences exist in particular concerning tolerability and specific infection risks.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Viking Huss, Hannah Bower, Karin Hellgren, Thomas Frisell, Johan Askling, ARTIS grp
Summary: This study assessed the cancer risks associated with Janus kinase inhibitors (JAKi) compared to biological disease-modifying antirheumatic drugs (bDMARDs) in clinical practice. The results showed that, in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), the short-term risk of cancers other than non-melanoma skin cancer (NMSC) was not higher with JAKi compared to tumor necrosis factor inhibitors (TNFi), but there was evidence of an increased risk for NMSC.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Biochemistry & Molecular Biology
Lina Wirestam, Frida Jonsson, Helena Enocsson, Christina Svensson, Maria Weiner, Jonas Wettero, Helene Zachrisson, Per Eriksson, Christopher Sjowall
Summary: A study examined the association between anti-oxidized low-density lipoprotein (anti-oxLDL) antibodies and subclinical atherosclerosis in patients with different systemic lupus erythematosus (SLE) phenotypes. Anti-oxLDL levels were measured in SLE patients, healthy controls, and subjects with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). The results showed no significant difference in anti-oxLDL levels between SLE patients and healthy controls, but levels were significantly higher in AAV subjects. There was also a significant decrease in anti-oxLDL levels in the SLE group over a 3-year period. The study did not find strong associations between anti-oxLDL antibodies and vascular affection in SLE.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Awais Ahmad, Andre Brylid, Charlotte Dahle, Muna Saleh, Orjan Dahlstrom, Helena Enocsson, Christopher Sjowall
Summary: The detection of antinuclear antibodies is crucial for diagnosing and predicting the outcome of systemic lupus erythematosus (SLE), primary Sjogren's syndrome (pSS), and mixed connective tissue disease (MCTD). Anti-U1-RNP and anti-RNP70 antibodies were examined in patients with SLE, pSS, and MCTD. The presence of anti-U1-RNP antibodies was associated with a clinical phenotype resembling MCTD and less organ damage in SLE patients. However, subtyping anti-RNP70 in anti-U1-RNP-positive sera did not provide significant clinical value.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Pediatrics
Per Lewander, Lina Wirestam, Charlotte Dahle, Jonas Wettero, Christopher Sjowall
Summary: The biomarker suPAR shows potential in predicting the risk of joint damage in early-stage idiopathic arthritis (JIA) patients. Elevated suPAR levels are associated with polyarticular involvement and joint erosions, suggesting that suPAR analysis could aid treatment decision-making and follow-up in JIA.
PEDIATRIC RHEUMATOLOGY
(2023)
Article
Rheumatology
M-l Karlsson, K. Hertzberg-Nyquist, S. Saevarsdottir, I. E. Lundberg, I Demmelmaier, S. Pettersson, K. Chatzidionysiou
Summary: The objective of this study was to evaluate an individually tailored smoking-cessation intervention in rheumatology care and compare characteristics of patients who quit smoking with those who did not. The results showed that 21% of patients quit smoking after 24 months, with a significant reduction in the number of cigarettes per day for those who still smoked. Patients with anxiety were less successful in quitting smoking.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
(2023)
Article
Immunology
Jesper Karlsson, Jonas Wettero, Lawrence A. Potempa, Rafael Fernandez-Botran, Yasmine O'Neill, Lina Wirestam, Fariborz Mobarrez, Christopher Sjowall
Summary: This study found an abundance of both pCRP and mCRP on extracellular vesicles (EVs) in systemic lupus erythematosus (SLE) patients, with elevated mCRP+ EVs in patients with active disease and in anti-CRP positive patients. Additionally, the proportions of mCRP+ EVs were lower in patients with acquired organ damage and displayed an inverse relationship with disease duration in lupus nephritis (LN) and patients with active disease. These findings suggest the relevance of EV-bound mCRP in SLE pathogenesis and its potential role in the development of anti-CRP autoantibodies by stimulating an immune response.
JOURNAL OF AUTOIMMUNITY
(2023)
Article
Immunology
Mike Aoun, Ana Coelho, Alexander Kramer, Amit Saxena, Pierre Sabatier, Christian Michel Beusch, Erik Lonnblom, Manman Geng, Nhu-Nguyen Do, Zhongwei Xu, Jingdian Zhang, Yibo He, Laura Romero Castillo, Hassan Abolhassani, Bingze Xu, Johan Viljanen, Joanna Rorbach, Gonzalo Fernandez Lahore, Inger Gjertsson, Alf Kastbom, Christopher Sjowall, Jan Kihlberg, Roman A. Zubarev, Harald Burkhardt, Rikard Holmdahl
Summary: The study reveals that autoreactive antigen-specific naive B cells tolerize infiltrating T cells against self-antigens to impede the development of tissue-specific autoimmune inflammation.
JOURNAL OF EXPERIMENTAL MEDICINE
(2023)
Correction
Immunology
Mike Aoun, Ana Coelho, Alexander Kramer, Amit Saxena, Pierre Sabatier, Christian Michel Beusch, Erik Lonnblom, Manman Geng, Nhu-Nguyen Do, Zhongwei Xu, Jingdian Zhang, Yibo He, Laura Romero Castillo, Hassan Abolhassani, Bingze Xu, Johan Viljanen, Joanna Rorbach, Gonzalo Fernandez Lahore, Inger Gjertsson, Alf Kastbom, Christopher Sjowall, Jan Kihlberg, Roman A. Zubarev, Harald Burkhardt, Rikard Holmdahl
JOURNAL OF EXPERIMENTAL MEDICINE
(2023)
Article
Rheumatology
C. Feldthusen, M. Hallstrom, A. d'Elia, A. Deminger, U. Kiltz, H. Forsblad-d'Elia
Summary: The objective of this study was to translate the ASAS HI EFIS into Swedish and culturally adapt it for a Swedish context, and to assess the construct validity of the Swedish version of ASAS HI and test-retest reliability in ASAS HI and EFIS in Swedish patients with AS. The results showed that the Swedish version of ASAS HI is valid and reliable, and recommended for assessing the impact of AS on global functioning and health.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
Elizabeth V. V. Arkema, Muna Saleh, Julia F. F. Simard, Christopher Sjoewall
Summary: This study examined the variations in prevalence and incidence of systemic lupus erythematosus (SLE) in a geographically defined area of central Sweden over a 14-year period. The results showed that the prevalence and incidence of SLE remained constant over this time period, and the disease phenotypes at onset were similar. This study is important for understanding the epidemiology and characteristics of SLE in the region.
ACR OPEN RHEUMATOLOGY
(2023)